Lamis Eldjerou

Non-Hodgkin lymphoma (NHL) is the seventh most frequently diagnosed cancer in the United States, and is expected to account for 4.23% of all new cancer cases in 2020.1 Diffuse large B-cell lymphoma (DLBCL) is the most common subtype of NHL, with more than 18,000 new cases diagnosed annually.2 The prevalence of DLBCL is projected to increase by nearly 20% in the next 15 years.3 Approximately 66% of patients with DLBCL respond to standard therapy with rituximab and an anthracycline-containing...

A Gilligan, D Stetsovsky, H Varker, B Davis and M Bonafede are employees of Truven Health Analytics, an IBM Company, which was paid by Novartis for the development of this manuscript. M Bhor, L Eldjerou, A Urniasz and D Globe are employees of Novartis. This study was sponsored by Novartis Pharmaceuticals Corporation, Oncology, NJ, USA.